Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Beyond Air Shares Continue Rally as Analysts Raise Price Targets

Published 11/16/2021, 04:58 AM
Updated 11/16/2021, 04:58 AM
© Reuters.

© Reuters.

By Sam Boughedda

Investing.com — Shares of Beyond Air Inc (NASDAQ:XAIR) have continued Friday's surge, currently trading around 10% higher.

After the medical device and pharmaceutical company reported earnings last Thursday, Truist and Oppenheimer analysts raised price targets for the stock.

Truist cited the FDA's review of the company's LungFit PH product progressing well, and Oppenheimer said that it was focusing on the company's PPHN launch. 

Truist analyst Gregory Fraser raised the price target on Beyond Air to $16 from $12, keeping a buy rating on the shares, while Oppenheimer analyst Suraj Kalia raised the firm's price target on the stock to $13 from $9, maintaining an outperform rating

Monday has seen Roth Capital join its colleagues, with analyst Scott Henry increasing the price target on Beyond Air shares to $15 from $11, keeping a buy rating, and saying that its earnings were "fundamentally as expected." 

The analyst also said that the company's nitric oxide therapy is underappreciated by investors, believing that Beyond Air is a leader in the technology. Henry also told investors that the Beyond Oncology spin-off was another reason for the price target change.

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.